.png)
.png)
Latest news from BIA
BIA reaction to Chancellor's announcement on no deal funding
A BIA spokesperson said: "The announced £434 million for medicines and medical products is significant investment, and recognition of the work of DHSC in this area, however we now need the detail of how the money will be spent.
UK Confirms its Leadership Position in Advanced Therapies
Cell and gene therapies and tissue-engineered products have the potential to offer a durable, life-changing effect, possibly with single administration New report from Alliance for Regenerative Medicine and UK BioIndustry Association highlights progress in financing and clinical trials 24% of Europe’s ATMP developers headquartered in the UK
BIA warns there is little time to avoid disruption as government announces ‘no-deal’ Brexit planning
Steve Bates OBE, CEO of the BIA responds to the Written Ministerial Statement on EU Exit preparedness published by the Government today.
UK Biotech forges links with new global investors
The UK BioIndustry Association (BIA) is hosting the key movers from the Hong Kong stock exchange in London this week as part of a strategic push to enable global investors to get to know the opportunities in UK biotech.
Opportunities for Ion Channel Targeting Antibodies: Current Landscape and Pipeline
Chronic pain is a massive clinical problem. We discuss the potential of subtype selective sodium channel blockers that may provide analgesia with limited side effects.
Kadans Science Partner invests in Stevenage UK enabling future growth of the research & development base
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
In ovo model for immuno-oncology screening
Inovotion seek academic or industry partners able to provide diverse immuno-oncology (IO) compounds, with preclinical data available, to validate their in ovo model.
Virtual Disease Laboratories: exploiting in silico models in the pharmaceutical industry
Simomics seek collaborators with in silico disease models with 3Rs benefits, to be enhanced through Virtual Disease Laboratories.
Engineering biology pitching competition
Early-stage engineering biology companies are welcome to register their interest to pitch at the UK Bioscience Forum.
CEO Update | Monday 19 August 2019
On Thursday the Department of Health (DHSC) announced its procurement exercise for an express freight service contract to deliver medicines and medical supplies into the country in the event of a no-deal Brexit. This new £25m contract is intended to deliver small parcels of medicines or medical products on a 24-hour basis, with additional provision to move larger pallet quantities on a two to four-day basis. The contract will run for 12 months, with a possible further 12-month extension. The contract notice has been published in the Official Journal of the European Union and potential bidders have until August 21 to submit proposals, with the successful provider or providers likely to be announced in September.
Guest blog | A guide to the SPC manufacturing waiver
The BIA has published a new guide for members on the supplementary protection certificate (SPC) manufacturing waiver, which has recently been introduced in the EU. Here, the lead author, Andrew Hutchison, explains why the BIA’s IP Advisory Committee has produced the guide.
Preparing for the Spending Review | Part 5: What the fast-tracked spending round means for biotech
In this fifth edition in our blog series on the 2019 Spending Review, BIA’s Policy and Public Affairs Manager Eric Johnsson looks at what the recently announced fast-tracked spending round means for our sector.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
